These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 30961942

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR.
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
    Oh PI, Lanctôt KL, Yoon A, Lee DS, Paes BA, Simmons BS, Parison D, Manzi P, Composs Investigators.
    Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
    [Abstract] [Full Text] [Related]

  • 6. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
    Oncel MY, Mutlu B, Kavurt S, Baş AY, Demirel N, Akyol M, Erdeve O, Dilmen U.
    Turk J Pediatr; 2012 Jun; 54(4):344-51. PubMed ID: 23692714
    [Abstract] [Full Text] [Related]

  • 7. Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan.
    Kusuda S, Takahashi N, Saitoh T, Terai M, Kaneda H, Kato Y, Ohashi A, Watabe S, Joh-o K, Hirai K.
    Pediatr Int; 2011 Jun; 53(3):368-73. PubMed ID: 20854284
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain.
    Figueras-Aloy J, Carbonell-Estrany X, Quero J, IRIS Study Group.
    Pediatr Infect Dis J; 2004 Sep; 23(9):815-20. PubMed ID: 15361718
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
    Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V, Mueller WD.
    Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
    [Abstract] [Full Text] [Related]

  • 11. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use.
    Prais D, Schonfeld T, Amir J, Israeli Respiratory Syncytial Virus Monitoring Group.
    Pediatrics; 2003 Sep; 112(3 Pt 1):548-52. PubMed ID: 12949282
    [Abstract] [Full Text] [Related]

  • 12. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
    Singleton R, Dooley L, Bruden D, Raelson S, Butler JC.
    Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.
    Kua KP, Lee SWH.
    Pharmacotherapy; 2017 Jun; 37(6):755-769. PubMed ID: 28423192
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [Abstract] [Full Text] [Related]

  • 17. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee.
    Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee.
    Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.